18F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma
暂无分享,去创建一个
W. Reddick | Junyu Guo | A. Bahrami | N. Daw | B. Shulkin | M. B. McCarville | J. Jenkins | S. Snyder | F. Navid | Jianrong Wu | J. C. Davis | C. Billups | V. Santana
[1] Binsheng Zhao,et al. Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] James R. Anderson,et al. 18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG). , 2016 .
[3] D. Jeon,et al. Initial Metabolic Tumor Volume Measured by 18F-FDG PET/CT Can Predict the Outcome of Osteosarcoma of the Extremities , 2013, The Journal of Nuclear Medicine.
[4] B. Fuchs,et al. Characterization of Different Osteosarcoma Phenotypes by PET Imaging in Preclinical Animal Models , 2013, The Journal of Nuclear Medicine.
[5] D. Jeon,et al. 18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[6] Liu Hongtao,et al. 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis. , 2012, Surgical oncology.
[7] Paul A Meyers,et al. Outcome for adolescent and young adult patients with osteosarcoma , 2012, Cancer.
[8] G. Treglia,et al. The Role of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Assessing the Response to Neoadjuvant Treatment in Patients with Osteosarcoma , 2012, International journal of molecular imaging.
[9] N. Thacker,et al. Quantifying heterogeneity in human tumours using MRI and PET. , 2012, European journal of cancer.
[10] L. Chukoskie,et al. Prediction of Chemotherapy Response by PET-CT in Osteosarcoma: Correlation With Histologic Necrosis , 2011, Journal of pediatric hematology/oncology.
[11] Shishir Rastogi,et al. Role of MRI in osteosarcoma for evaluation and prediction of chemotherapy response: correlation with histological necrosis , 2011, Pediatric Radiology.
[12] Drew A. Torigian,et al. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[13] Min Suk Kim,et al. Prediction Model of Chemotherapy Response in Osteosarcoma by 18F-FDG PET and MRI , 2009, Journal of Nuclear Medicine.
[14] Roland L Bassett,et al. 18F-FDG PET/CT as an Indicator of Progression-Free and Overall Survival in Osteosarcoma , 2009, Journal of Nuclear Medicine.
[15] S. Dry,et al. Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas , 2008, Journal of Nuclear Medicine.
[16] Michael E. Phelps,et al. Reduction of Glucose Metabolic Activity Is More Accurate than Change in Size at Predicting Histopathologic Response to Neoadjuvant Therapy in High-Grade Soft-Tissue Sarcomas , 2008, Clinical Cancer Research.
[17] Ren-Shyan Liu,et al. Comparison Between F‐18‐FDG Positron Emission Tomography and Histology for the Assessment of Tumor Necrosis Rates in Primary Osteosarcoma , 2006, Journal of the Chinese Medical Association : JCMA.
[18] J. Eary,et al. [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] E. Kleinerman,et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] A. Huvos,et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Rosen,et al. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.
[22] H. Min,et al. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[23] A. Huvos,et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G Rosen,et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.